In vitro metabolism and the effect on human cytochrome P450s of garenoxacin

Japanese Journal of Chemotherapy

Volumn 55, Issue , 1997, Pages 87-94

  Nakamura, Tetsuro ^a   Tobise, Chie ^a   Kato, Hiroshi ^a   Katai, Masaki ^a   Hayakawa, Hiroyoshi ^a   Todo, Yozo ^a  

^a TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

cytochrome P450; drug drug interaction; garenoxacin

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; GARENOXACIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTICLE; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CULTURE; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION;

EID: 35349024972     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: 10.11250/chemotherapy1995.55.Supplement1_87     Document Type: Article

References (14)

1. Takahata M, Mitsuyama J, Yamashiro Y, Yonezawa M, Araki H, Todo Y, et al : In vitro and in vivo antimicrobial activities of T-3811 ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother 1999; 43 : 1077-84
2. Fung-Tomc J C, Minassian B, Kolek B, Huczko E, Aleksunes L, Stickle T, et al : Antibacterial spectrum of a novel des-fluoro (6) quinolone, BMS-284756. Antimicrob Agents Chemother 2000; 44 : 3351-6
3. Hayakawa H, Fukushima Y, Kato H, Fukumoto H, Kadota T, Yamamoto H, et al : Metabolism and disposition of novel des-fluoro quinolone garenoxacin in experimental animals and an interspecies scaling of pharmacokinetic parameters. Drug Metab Dispos 2003; 31 : 1409-18
4. Waxman D J, Ko A, Walsh C : Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. J Biol Chem 1983; 258 : 11937-47
5. Aitio A : A simple and sensitive assay of 7-ethoxycoumarin deethylation. Anal Biochem 1978; 85 : 488-91
6. Okuyama M, Inoue C, Aijima K, Nakamura Y, Kaburagi T, Shigematsu A : In vitro method for assessing hepatic drug metabolism. Biol Pharm Bull 1997; 20 : 1-5
7. Bello A, Stewart C, O'Mara E, Christopher L, Gajjar D A : Absolute oral bioavailability of garenoxacin tablets and the bioequivalence of the intravenous formulation with respect to oral tablets. American Society of Health-System Pharmacists, Midyear Clinical Meeting in Atlanta, December 2002; #321
8. Bello A, Farmer J, O'Mara E, Christopher L, Gajjar D A : Pharmacokinetics and disposition of [14C]-garenoxacin in healthy adult male subject. American Society of Health-System Pharmacists, Midyear Clinical Meeting in Atlanta, December 2002; #331
9. Bello A, Hollenbauch D, Gajjar D, Christopher L, Grasela D : Ex vivo serum protein binding of BMS-284756 : Impact on the unbound AUC/MIC ratio for Streptococcus pneumoniae. Abstr 41st Intersci Conf Antimicrob Agents Chemother in Chicago, September 2001; p.8, A-45
10. Davies B, Morris T : Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10 : 1093-5
11. Wijnands W J, van Herwaarden C L, Vree T B : Enox-acin raises plasma theophylline concentrations. Lancet 1984; 2 : 108-9
12. Fuhr U, Anders E M, Mahr G, Sorgel F, Staib A H : Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother 1992; 36 : 942-8
13. Stahlmann R, Lode H : Safety overview : Toxicity, adverse effects, and drug interactions. In Andriole V T (ed.), The quinolones, 3rd ed., Academic Press, California, 2000; p. 398-454
14. Kobayashi Y, Sakai R, Ohshiro N, Ohbayashi M, Kohyama N, Yamamoto T : Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos 2005; 33 : 619-22